These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31657017)

  • 1. Prognostic significance of monoclonal gammopathy in diffuse large B-cell lymphoma.
    Papageorgiou SG; Thomopoulos TP; Spathis A; Bouchla A; Glezou I; Stavroulaki G; Gkontopoulos K; Bazani E; Foukas PG; Pappa V
    Hematol Oncol; 2019 Dec; 37(5):634-637. PubMed ID: 31657017
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Lüscher D; Diethelm M; Hundsberger T; Hitz F
    Praxis (Bern 1994); 2018; 107(6):329-333. PubMed ID: 29536816
    [No Abstract]   [Full Text] [Related]  

  • 3. Atypical lymphocytosis, cold agglutinin hemolytic anemia, and monoclonal gammopathy in an HIV patient with marrow involvement by diffuse large B-cell lymphoma.
    Chen M; Abedi M
    Blood; 2013 Nov; 122(23):3711. PubMed ID: 24427808
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.
    Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS
    Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma.
    Li Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Fan L; Li JY; Xu W
    Br J Haematol; 2018 Jul; 182(1):131-134. PubMed ID: 28493470
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.
    Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
    Am J Hematol; 2016 May; 91(5):529-37. PubMed ID: 27093913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Results of Rituximab Pre- and Post-BEAM with or without
    Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
    Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
    [No Abstract]   [Full Text] [Related]  

  • 9. Neurologic Complications of Lymphoma, Leukemia, and Paraproteinemias.
    Mauermann ML
    Continuum (Minneap Minn); 2017 Jun; 23(3, Neurology of Systemic Disease):669-690. PubMed ID: 28570324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
    Beygi S; Sadashiv S; Reilly JB; Khan C; Lister J
    Leuk Lymphoma; 2018 Dec; 59(12):2847-2861. PubMed ID: 29616868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of the prognostic nutritional index in very elderly patients over 80 years of age with diffuse large B-cell lymphoma.
    Hamada E; Shinji O; Nishiyama-Fujita Y; Akiimoto M; Tanigawa T; Ito C; Sakurai A; Aisa Y; Nakazato T
    Ann Hematol; 2020 May; 99(5):1153-1155. PubMed ID: 32270216
    [No Abstract]   [Full Text] [Related]  

  • 12. IgA monoclonal gammopathy accompanying extranodal B cell lymphomas.
    Wu B; Chen P; Wang W; Li F; Zou S; Cheng Y
    Ann Hematol; 2014 Mar; 93(3):521-2. PubMed ID: 23793917
    [No Abstract]   [Full Text] [Related]  

  • 13. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
    Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
    Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.
    Chiappella A; Castellino A; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Apr; 10(4):289-297. PubMed ID: 28290728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era.
    Papageorgiou SG; Kontos CK; Foukas PG; Panopoulou E; Vasilatou D; Rapti SM; Gkontopoulos K; Bazani E; Panayiotides IG; Dimitriadis G; Scorilas A; Pappa V
    Leuk Lymphoma; 2016 Sep; 57(9):2199-203. PubMed ID: 27442703
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Furlan C; Spina M; Tucci A; Rigacci L; Iotti C; Vitolo U; Ricardi U; Merli F
    Leuk Lymphoma; 2016 Nov; 57(11):2677-80. PubMed ID: 26926887
    [No Abstract]   [Full Text] [Related]  

  • 19. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
    Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.